SOPH
SOPHiA GENETICS S.A.
$7.15
-0.23
(-3.12%)
Mkt Cap
599.85M
Volume
432,749
52W Range
3.75-8.98
Sector
Healthcare
Beta
0.95
EPS (TTM)
-1.15 USD
P/E Ratio
-3.99
Revenue (TTM)
86.17M USD
Rev Growth (5Y)
+22.2%
EPS Growth (5Y)
N/A
Company Description
SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 77.27M | 65.17M | 62.37M | 47.56M | 40.45M | 28.40M | 25.36M |
| Net Income | (79.00M) | (62.49M) | (78.98M) | (87.45M) | (73.67M) | (39.34M) | (33.79M) |
| EPS | -1.17 | -0.95 | -1.22 | -1.36 | -1.33 | -0.82 | -0.53 |
| Free Cash Flow | (38.59M) | (51.00M) | (57.80M) | (80.47M) | (64.61M) | (34.93M) | (34.71M) |
| FCF / Share | -0.57 | -0.78 | -0.89 | -1.26 | -1.17 | -0.73 | -0.54 |
| Operating CF | (38.01M) | (42.82M) | (48.58M) | (70.09M) | (57.94M) | (31.73M) | (31.68M) |
| Total Assets | 163.46M | 155.31M | 206.16M | 243.84M | 320.17M | 132.12M | 51.66M |
| Total Debt | 63.02M | 30.03M | 18.60M | 16.74M | 13.06M | 7.25M | 8.46M |
| Cash & Equiv | 70.29M | 80.23M | 123.25M | 161.31M | 192.96M | 74.62M | 18.07M |
| Book Value | 47.15M | 96.49M | 151.44M | 200.13M | 275.40M | 100.51M | 22.25M |
| Return on Equity | -1.68 | -0.65 | -0.52 | -0.44 | -0.27 | -0.39 | -1.52 |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23.31M | 21.69M | 21.71M | 19.46M | 18.32M | 17.78M | 17.73M | 15.85M | 15.81M | 15.78M | 17.05M | 16.30M |
| Net Income | (22.36M) | (19.32M) | (19.18M) | (20.02M) | (22.41M) | (17.39M) | (15.16M) | (18.44M) | (15.19M) | (13.70M) | (24.06M) | (13.82M) |
| EPS | -0.30 | -0.27 | -0.28 | -0.30 | -0.33 | -0.26 | -0.23 | -0.28 | -0.23 | -0.21 | -0.37 | -0.21 |
| Free Cash Flow | (10.39M) | (17.06M) | (9.28M) | (8.90M) | (10.19M) | (12.24M) | (12.54M) | (9.48M) | (12.37M) | (16.60M) | (13.54M) | (14.27M) |
| FCF / Share | -0.14 | -0.24 | -0.14 | -0.13 | -0.15 | -0.18 | -0.19 | -0.14 | -0.19 | -0.25 | -0.21 | -0.22 |
| Operating CF | (7.69M) | (16.18M) | (8.94M) | (8.79M) | (8.21M) | (10.75M) | (10.60M) | (7.16M) | (10.42M) | (14.64M) | (11.29M) | (12.17M) |
| Total Assets | 198.36M | 157.00M | 163.03M | 163.46M | 177.62M | 146.72M | 155.31M | 177.61M | 181.10M | 180.26M | 206.16M | 205.85M |
| Total Debt | 61.83M | 62.42M | 63.02M | 63.37M | 63.81M | 30.13M | 30.03M | 31.67M | 30.07M | 17.44M | 18.60M | 17.87M |
| Cash & Equiv | 107.67M | 65.39M | 70.29M | 81.61M | 94.82M | 68.53M | 80.23M | 95.79M | 105.40M | 103.73M | 123.25M | 132.77M |
| Book Value | 83.12M | 45.69M | 47.15M | 60.69M | 76.69M | 85.61M | 96.49M | 113.51M | 121.44M | 132.23M | 151.44M | 158.44M |
| Return on Equity | -0.27 | -0.42 | -0.41 | -0.33 | -0.29 | -0.20 | -0.16 | -0.16 | -0.13 | -0.10 | -0.16 | -0.09 |
SOPH News
SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signals
SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcript
SOPHiA GENETICS Q2 Earnings Call Highlights
SOPHiA GENETICS Reports Second Quarter 2026 Results
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026
SOPHiA GENETICS Publishes Results of the 2026 Annual General Meeting
SOPHiA GENETICS Announces Closing of $57.5 Million Public Offering of Ordinary Shares With Full Exercise of the Underwriters' Option to Purchase Additional Shares